No Data
CHINARES PHARMA: Interim Report 2024
Credit Suisse: Maintains 'Shareholding' rating for Chinares Pharma (03320), target price lowered to HKD 7.5.
Daiwa Securities has lowered its profit forecast for Chinares Pharma from 2024 to 2030 by 7% to 9%.
China Resources Pharmaceutical Group (HKG:3320) Has A Pretty Healthy Balance Sheet
[Brokerage Focus] China Securities Co.,Ltd. maintains a "buy" rating for chinares pharma (03320), stating that the company's commercial sector is expected to grow steadily in the second half of the year.
Jingu Finance News | China Securities Co., Ltd. released a research report pointing out that Chinares Pharma (03320) issued its 2024 interim performance announcement. In the first half of the year, it achieved revenue of 128.598 billion yuan, a year-on-year growth of 4.7%; realized a net income attributable to the parent company of 2.605 billion yuan, a year-on-year decrease of 2.9%, with earnings per share of 0.41 yuan, lower than expected. Looking ahead to the second half of 2024, the bank believes that the commercial sector has a relatively low base, and pharmaceutical demand may gradually be released, with the company's commercial sector expected to grow steadily; as the industrial sector layout gradually optimizes and resource integration progresses continuously, the industrial sector is expected to maintain stable growth.
Hong Kong stocks are volatile | chinares pharma (03320) fell by more than 5% again, institutions say the industry environment is declining, and the company's distribution business growth may slow down internally.
China Resources Pharma (03320) fell more than 5%, as of the time of writing, down 4.47%, at HK$4.92, with a turnover of HK$76.604 million.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
No Data
No Data
